STOCK TITAN

Alterity, FDA align on key ATH434 Phase 3 trial elements

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

At its 2026 AGM, Alterity Therapeutics Chairman Julian Babarczy said the company has FDA alignment on key elements of ATH434’s Phase 3 trial design and potential registrational pathway for multiple system atrophy (MSA). The company also reported producing its first registration batch of ATH434 and receiving a new US composition-of-matter patent extending protection to 2045.

Alterity finished September with A$41.3 million in cash. The board said Phase 3 will require a substantial financial commitment and that securing funding and a development structure is a priority. It is evaluating potential pharmaceutical partnerships and other strategic and capital funding options; operational preparations are underway.

Cash A$41.3 million At the end of September
Patent protection 2045 A new US composition-of-matter patent extends protection to this year
registrational pathway regulatory
"potential registrational pathway for a Phase 3 trial of ATH434 in MSA"
Multiple System Atrophy medical
"Multiple System Atrophy, or MSA"
A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.
registration batch technical
"successful production of our first registration batch of ATH434"
composition of matter patent technical
"a new US composition of matter patent extending protection to 2045"
A composition of matter patent is a legal right that protects a specific chemical, molecule, material or formulated mixture—think of it as locking down a unique recipe for a substance. For investors it matters because the patent can give a company exclusive control to make, sell, or license that substance, creating a potential source of revenue and a competitive barrier similar to owning the only map to a valuable resource.
randomized, double-blind, placebo-controlled medical
"randomized, double-blind, placebo-controlled Phase 2 clinical trial"
A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ATHE say about ATH434’s Phase 3 trial?

Alterity said it has FDA alignment on key elements of the trial design and potential registrational pathway for ATH434 in MSA. It also said operational preparations are underway and that it aims to secure resources to commence the pivotal trial.

How much cash did ATHE have at September’s end?

Alterity reported A$41.3 million in cash at September’s end.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Chairman's Address to 2026 AGM and CEO Presentation to AGM

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Alterity Therapeutics Limited

     
 

By:

/s/ Julian Babarczy

   

Julian Babarczy

   

Chairman

 

Date: November 20, 2026

 

2

Exhibit 99.1

 

logo.jpg

 

Chairman’s Address 2026 Annual General Meeting

 

Good morning, ladies and gentlemen, and welcome to Alterity Therapeutics' 2026 Annual General Meeting. For those I haven't had the opportunity to meet, my name is Julian Babarczy, and I am the Chairman of Alterity.

 

This is my first AGM as Chairman, having joined the Board of Directors following last year's AGM. It has been a particularly important and productive period for the Company, and I would like to take a few minutes to reflect on the progress we have made, and importantly, what that means for our future.

 

When I joined the Board, Alterity had delivered exceptional Phase 2 clinical results for ATH434 in Multiple System Atrophy, or MSA. However, a number of important questions remained around the regulatory pathway, the design of a pivotal Phase 3 trial, and the preparations required to take the program forward.

 

Over the past twelve months, we have made substantial progress in addressing those questions. Most significantly, following a series of constructive interactions with the US Food and Drug Administration (FDA), we now have alignment on the key elements of the design and potential registrational pathway for a Phase 3 trial of ATH434 in MSA.

 

This is a significant achievement for Alterity. It provides a clear framework for the next phase of development and allows us to move forward with considerably greater clarity around what is required. David will provide more detail on the FDA feedback and our Phase 3 trial design in his presentation shortly.

 

While there is still important work ahead, we believe the progress made over the past year has significantly strengthened our development program and provides a solid foundation as we move towards Phase 3.

 

In many respects, the past twelve months have represented an important transition for Alterity. We have moved from establishing encouraging clinical evidence to having a defined pathway towards a potential FDA registrational program. I believe this represents an important step forward in the maturity of the Company and the opportunity we are pursuing.

 

 

 

Alongside the regulatory progress, we have continued to build our scientific evidence base. Further analyses of our Phase 2 results, together with publications and presentations at major international scientific conferences, have strengthened our understanding of ATH434 and helped inform the design of the pivotal trial.

 

We have also made important progress in manufacturing, including the successful production of our first registration batch of ATH434, and strengthened our intellectual property position with a new US composition of matter patent extending protection to 2045.

 

Taken together, these developments are important not only from a clinical and regulatory perspective, but also commercially. They strengthen the potential value of ATH434 and our ability to pursue the best development and strategic opportunities for the asset.

 

I also want to acknowledge the significant unmet medical need we are seeking to address. MSA is a devastating, rapidly progressive neurological disease, with no approved treatment currently available to slow its progression. The potential to make a meaningful difference to patients and their families remains central to everything we do.

 

The past year has also seen some changes to the composition of our Board, reflecting the evolution of Alterity and the opportunities ahead.

 

We welcomed Ann Cunningham to the Board in April, bringing extensive global pharmaceutical and commercial experience, particularly in neurology. Together with the changes to the Board over the past year, we believe we now have a strong and complementary mix of scientific, pharmaceutical, commercial, financial and governance expertise.

 

As we move towards Phase 3, the decisions facing Alterity will increasingly involve significant capital commitments, potential strategic partnerships and the execution of a global clinical program. We believe the Board and management team are well positioned to execute, and to provide the oversight, strategic direction and commercial judgement required during this next stage.

 

I would also like to acknowledge and thank those directors who have stepped down from the Board over the past year for their contribution and service to Alterity.

 

As we look ahead, we are sharpening our focus on the next important phase of Alterity's development: securing the funding required to advance and successfully execute our Phase 3 program.

 

 

 

We finished September with A$41.3 million in cash, providing an important financial foundation as we advance our preparations. However, Phase 3 will require a substantial financial commitment, and securing the appropriate funding and development structure remains a key priority for the Board. We continue to evaluate a range of alternatives, including potential pharmaceutical partnerships and other strategic and capital funding options.

 

Our responsibility as a Board is to carefully assess these opportunities, balancing the need to advance ATH434 efficiently with the importance of preserving its substantial potential value and maximising long-term returns for our shareholders.

 

Looking forward, we have a clear objective: to secure the resources required to commence our pivotal Phase 3 trial and position the Company to execute it successfully. Operational preparations are already underway, and David will provide more detail on these activities shortly.

 

I am encouraged by what the team has achieved over the past year and have great confidence in the quality of our people and the program we are advancing.

 

On behalf of the Board, I would like to thank David and the entire Alterity team for their dedication and commitment, together with our clinical investigators and collaborators around the world.

 

Most importantly, I want to acknowledge the patients and their families who continue to support our research. Their contribution is fundamental to the progress we are making, and a constant reminder of why this work matters.

 

And finally, to our shareholders, thank you for your continued support.

 

Alterity enters this next stage of its development in a materially stronger position than twelve months ago. We have a defined regulatory pathway, an increasingly robust body of clinical evidence, strengthened intellectual property and a clear understanding of the next steps required to advance ATH434.

 

There is considerable work ahead, but I believe we have an exciting opportunity before us. The Board and management remain focused on translating the progress made to date into meaningful outcomes for patients and long-term value for our shareholders. Thank you, and I will now hand over to David for his presentation.

 

 

 

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson’s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company’s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

 

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

 

Contacts:

 

Investors

Elyse Shapiro

ir@alteritytx.com

 

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

 

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

 

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

 

 

slide01.jpg

 

 

 
slide02.jpg

 

 

 
slide03.jpg

 

 

 
slide04.jpg

 

 

 
slide05.jpg

 

 

 
slide06.jpg

 

 

 
slide07.jpg

 

 

 
slide08.jpg

 

 

 
slide09.jpg

 

 

 
slide10.jpg

 

 

 
slide11.jpg

 

 

 
slide12.jpg

 

 

Filing Exhibits & Attachments

1 document

Keep reading